Patient monitoring and follow-up in lentiviral clinical trials

Autor: Carl H. June, Andrew R. Zolopa, Kris Andre, David Stein, Gary Blick, Clifford Kinder, Pablo Tebas, Laurent Humeau, Gwen Binder-Scholl, Tessio Rebello, April Winemiller, Gloria Hoyah, Gerard J. McGarrity, Richard N. Greenberg
Rok vydání: 2013
Předmět:
Zdroj: The Journal of Gene Medicine. 15:78-82
ISSN: 1099-498X
DOI: 10.1002/jgm.2691
Popis: Background Lentiviral vectors are being used with increasing frequency in human clinical trials. We were the first to use lentiviral vectors in clinical trials in 2003. Our lentiviral vector encoded a long RNA antisense sequence to the HIV-1 envelope and was used in an ex vivo autologous setting to provide viral load control in HIV-1 positive subjects failing anti-HIV therapy. A total of 65 subjects have been treated in Phase 1 and Phase 2 trials in six institutions. Methods Good manufacturing practices (GMP) lots of the lentiviral vector used in our clinical trials were assayed for the presence of replication competent lentivirus (RCL). RCL assays were conducted at two stages. The first testing was performed on samples collected immediately following bulk harvest of the GMP product lot and consisted of 1 × 108 cells used in production. RCL assays were also performed on aliquots of the final fill of the vector by the inoculation of at least 5% of the GMP final fill volume into C8166 cells, passaged for at least ten passages and tested for RCL by p24 enzyme-linked immunosorbent assay and vesicular stomatitis virus-G envelope DNA. Results Following 263 infusions of autologous, transduced cells, no adverse events have been detected in these subjects, with some followed for more than 8 years following infusions. More than 4.3 × 1012 VRX496 proviral copies were administered to these 65 subjects. Conclusions Data from this small population suggest that there is no apparent risk for serious adverse events with the use of lentiviral vectors. Copyright © 2013 John Wiley & Sons, Ltd.
Databáze: OpenAIRE
Externí odkaz: